Chronic Pain Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes

DelveInsight's "Chronic Pain Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Pain, historical and forecasted epidemiology as well as the Chronic Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Pain Market Forecast
https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Pain Market Report:
• The Chronic Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In September 2025, FDA Commissioner Marty Makary, MD, MPH, highlighted the ongoing urgency of the opioid crisis, noting that physicians urgently need more alternatives to opioids for managing chronic pain. Although opioid prescribing has declined in recent years, the FDA reported that around one in five U.S. adults with chronic pain continues to receive opioid prescriptions due to a lack of effective options. While not all long-term users develop misuse issues, the CDC estimates that 8% to 12% of patients on prolonged opioid therapy experience misuse.
• In March 2025, Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company developing innovative therapies for neuroscience, inflammation, and immunology (NI&I) conditions, has announced the initiation of patient dosing in its exploratory Phase 1b trial of PIPE-791. This randomized, double-blind, placebo-controlled, crossover study focuses on chronic pain. PIPE-791 is a novel, brain-penetrant small molecule that acts as an antagonist of the lysophosphatidic acid 1 receptor (LPA1R).
• In March 2025, Tris Pharma, Inc., a commercial-stage biopharmaceutical company, announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal trial assessing cebranopadol, an investigational treatment for moderate-to-severe acute pain following bunionectomy surgery. The company also shared further encouraging data from the ALLEVIATE-1 Phase 3 trial in patients who underwent abdominoplasty, for which topline findings were recently reported.
• In February 2025, BioRestorative Therapies announced that the FDA cleared its Investigational New Drug (IND) application for BRTX-100, a novel cell-based therapeutic for treating chronic cervical discogenic pain (cCDP) by targeting areas with little blood flow.
• In January 2025, Zynex Inc. expanded its portfolio of non-invasive medical devices for pain management and rehabilitation. The FDA recently cleared Zynex's TensWave device, which uses Transcutaneous Electrical Nerve Stimulation (TENS) therapy for portable, drug-free pain relief. Zynex's flagship NexWave device, clinically proven to reduce chronic pain, combines multiple therapeutic modalities for effective pain management.
• In 2023, the United States recorded the highest prevalence of chronic pain cases among the total 7MM regions.
• Among the EU4 and the UK, the United Kingdom had the highest prevalence of chronic pain cases, accounting for approximately 30%.
• The prevalence of chronic pain increased with age, with the highest rates observed in individuals aged 45 to 64 years.
• In 2023, around 70% of chronic pain cases in the United States were classified as moderate to severe in terms of severity.
• Key Chronic Pain Companies: Seikagaku Corporation/Chiltern International, Pacira BioSciences, Paradigm Biopharmaceuticals, Tonix Pharmaceuticals, and others
• Key Chronic Pain Therapies: JOYCLU (diclofenac etalhyaluronate sodium), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), ZILOSUL (pentosan polysulfate sodium),TNX-102 SL, and others
• The Chronic Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Pain pipeline products will significantly revolutionize the Chronic Pain market dynamics.

Chronic Pain Overview
Chronic Pain is a type of nerve damage caused by prolonged high blood sugar levels in individuals with diabetes. It typically affects the feet and legs, leading to symptoms like burning, tingling, sharp pain, or numbness. This condition occurs when high blood sugar damages the nerves, resulting in abnormal pain signals. The pain can be persistent and difficult to manage, affecting daily activities. Treatment often includes pain relievers, anticonvulsants, antidepressants, and lifestyle changes to help control blood sugar levels and manage symptoms.

Get a Free sample for the Chronic Pain Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Pain Epidemiology Segmentation:
The Chronic Pain market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Pain
• Prevalent Cases of Chronic Pain by severity
• Gender-specific Prevalence of Chronic Pain
• Diagnosed Cases of Episodic and Chronic Chronic Pain

Download the report to understand which factors are driving Chronic Pain epidemiology trends @ Chronic Pain Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Pain market or expected to get launched during the study period. The analysis covers Chronic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Pain Therapies and Key Companies
• JOYCLU (diclofenac etalhyaluronate sodium): Seikagaku Corporation/Chiltern International
• ZILRETTA (triamcinolone acetonide extended-release injectable suspension): Pacira BioSciences
• ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals
• TNX-102 SL: Tonix Pharmaceuticals

Discover more about therapies set to grab major Chronic Pain market share @ Chronic Pain Treatment Landscape
https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Chronic Pain Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Pain Companies: Seikagaku Corporation/Chiltern International, Pacira BioSciences, Paradigm Biopharmaceuticals, Tonix Pharmaceuticals, and others
• Key Chronic Pain Therapies: JOYCLU (diclofenac etalhyaluronate sodium), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), ZILOSUL (pentosan polysulfate sodium),TNX-102 SL, and others
• Chronic Pain Therapeutic Assessment: Chronic Pain current marketed and Chronic Pain emerging therapies
• Chronic Pain Market Dynamics: Chronic Pain market drivers and Chronic Pain market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Pain Unmet Needs, KOL's views, Analyst's views, Chronic Pain Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.